Cochlin, a product of the COCH gene, is a major constituent of the inner ear extracellular matrix. Type II collagen, a protein that contributes to structural stability, is also a component of this extracellular matrix. In this study, using the postembedding immunogold method, we demonstrate the localization of cochlin and type II collagen in the cochlear duct at the ultrastructural level. The immunolabeling of cochlin was observed in the fibrillar substance in the spiral limbus, beneath the inner sulcus cells, and in the basilar membrane, the spiral prominence and the spiral ligament. Immunolabeling of type II collagen was observed in the same fibrillar substance in the extracellular matrix of the cochlear duct. This localization of cochlin is consistent with the expected localization of type II collagen. The localization of cochlin and type II collagen indicates the important roles played by these proteins in the hearing process.

1.
Baek MJ, Park HM, Johnson JM, Altuntas CZ, Jane-Wit D, Jaini R, Solares CA, Thomas DM, Ball EJ, Robertson NG, Morton CC, Hughes GB, Tuohy VK: Increased frequencies of cochlin-specific T cells in patients with autoimmune sensorineural hearing loss. J Immunol 2006;177:4203–4210.
2.
Bom SJ, Kemperman MH, de Kok YJ, Huygen PL, Verhagen WI, Cremers FP, Cremers CW: Progressive cochleovestibular impairment caused by a point mutation in the COCH gene at DFNA9. Laryngoscope 1999;109:1525–1530.
3.
Buckiova D, Popelar J, Syka J: Collagen changes in the cochlea of aged Fischer 344 rats. Exp Gerontol 2006;41:296–302.
4.
de Kok YJ, Bom SJ, Brunt TM, Kemperman MH, van Beusekom E, van der Velde-Visser SD, Robertson NG, Morton CC, Huygen PL, Verhagen WI, Brunner HG, Cremers CW, Cremers FP: A Pro51Ser mutation in the COCH gene is associated with late onset autosomal dominant progressive sensorineural hearing loss with vestibular defects. Hum Mol Genet 1999;8:361–366.
5.
Dreiling FJ, Henson MM, Henson OW Jr: The presence and arrangement of type II collagen in the basilar membrane. Hear Res 2002;166:166–180.
6.
Fransen E, Verstreken M, Verhagen WI, Wuyts FL, Huygen PL, D’Haese P, Robertson NG, Morton CC, McGuirt WT, Smith RJ, Declau F, Van de Heyning PH, Van Camp G: High prevalence of symptoms of Ménière’s disease in three families with a mutation in the COCH gene. Hum Mol Genet 1999;8:1425–1429.
7.
Grabski R, Szul T, Sasaki T, Timpl R, Mayne R, Hicks B, Sztul E: Mutations in COCH that result in non-syndromic autosomal dominant deafness (DFNA9) affect matrix deposition of cochlin. Hum Genet 2003;113:406–416.
8.
Ikezono T, Omori A, Ichinose S, Pawanker R, Watanabe A, Yagi T: Identification of the protein product of the Coch gene (hereditary deafness gene) as the major component of bovine inner ear protein. Biochim Biophys Acta 2001;1535:258–265.
9.
Ikezono T, Shindo S, Li L, Omori A, Ichinose S, Watanabe A, Kobayashi T, Pawankar R, Yagi T: Identification of a novel Cochlin isoform in the perilymph: insights to Cochlin function and the pathogenesis of DFNA9. Biochem Biophys Res Commun 2004;314:440–446.
10.
Ikezono T, Shindo S, Sekiguchi S, Hanprasertpong C, Li L, Pawankar R, Morizane T, Baba S, Koizumi Y, Sekine K, Watanabe A, Komatsuzaki A, Murakami S, Kobayashi T, Miura M, Yagi T: Cochlin-tomoprotein: a novel perilymph-specific protein and a potential marker for the diagnosis of perilymphatic fistula. Audiol Neurotol 2009;14:338–344.
11.
Ishii K, Murofushi T, Takeuchi N: Morphological changes in the tectorial and basilar membranes of aged rats. Eur Arch Otorhinolaryngol 1994;251:357–360.
12.
Kaname H, Yoshihara T, Ishii T, Tatsuoka H, Chiba T: Ultrastructural and immunocytochemical study of the subepithelial fiber component of the guinea pig inner ear. J Electron Microsc 1994;43:394–397.
13.
Khetarpal U, Schuknecht HF, Gacek RR, Holmes LB: Autosomal dominant sensorineural hearing loss. Pedigrees, audiologic findings, and temporal bone findings in two kindreds. Arch Otolaryngol Head Neck Surg 1991;117:1032–1042.
14.
Khetarpal U: Autosomal dominant sensorineural hearing loss. Further temporal bone findings. Arch Otolaryngol Head Neck Surg 1993;119:106–108.
15.
Khetarpal U: DFNA9 is a progressive audiovestibular dysfunction with a microfibrillar deposit in the inner ear. Laryngoscope 2000;110:1379–1384.
16.
Kommareddi PK, Nair TS, Raphael Y, Telian SA, Kim AH, Arts HA, El-Kashlan HK, Carey TE: Cochlin isoforms and their interaction with CTL2 (SLC44A2) in the inner ear. J Assoc Res Otolaryngol 2007;8:435–446.
17.
Manolis EN, Yandavi N, Nadol JB Jr, Eavey RD, McKenna M, Rosenbaum S, Khetarpal U, Halpin C, Merchant SN, Duyk GM, MacRae C, Seidman CE: A gene for non-syndromatic autosomal dominant progressive postlingual sensorineural hearing loss maps to chromosome 14q12–13. Hum Mol Genet 1996;5:1047–1050.
18.
Mizuta K, Ikezono T, Iwasaki S, Arai M, Hashimoto M, Pawankar R, Watanabe T, Shindo S, Mineta H: Ultrastructural co-localization of cochlin and type II collagen in the rat semicircular canal. Neurosci Lett 2008;434:104–107.
19.
Nagy I, Trexler M, Patthy L: The second von Willebrand type A domain of cochlin has high affinity for type I, type II and type IV collagens. FEBS Lett 2008;582:4003–4007.
20.
Nair TS, Kozma KE, Hoefling NL, Kommareddi PK, Ueda Y, Gong TW, Lomax MI, Lansford CD, Telian SA, Satar B, Arts HA, El-Kashlan HK, Berryhill WE, Raphael Y, Carey TE: Identification and characterization of choline transporter-like protein 2, an inner ear glycoprotein of 68 and 72 kDa that is the target of antibody-induced hearing loss. J Neurosci 2004;24:1772–1779.
21.
Robertson NG, Cremers CW, Huygen PL, Ikezono T, Krastins B, Kremer H, Kuo SF, Liberman MC, Merchant SN, Miller CE, Nador JB Jr, Sarracino DA, Verhagen WI, Morton CC: Cochlin immunostaining of inner ear pathologic deposits and proteomic analysis in DFNA9 deafness and vestibular dysfunction. Hum Mol Genet 2006;15:1071–1085.
22.
Robertson NG, Hamaker SA, Patriub V, Aster JC, Morton CC: Subcellular localization, secretion, and post-translational processing of normal cochlin, and of mutants causing the sensorineural deafness and vestibular disorder, DFNA9. J Med Genet 2003;40:479–486.
23.
Robertson NG, Jones SM, Sivakumaran TA, Giersch ABS, Jurado SA, Call LM, Miller CE, Maison SF, Liberman MC, Morton CC: A targeted Coch missense mutation: a knock-in mouse model for DFNA9 late-onset hearing loss and vestibular dysfunction. Hum Mol Genet 2008;17:3426–3434.
24.
Robertson NG, Lu L, Heller S, Merchant SN, Eavey RD, MacKenna M, Nadol JB Jr, Miyamoto RT, Linthicum FH Jr, Lubianca Neto JF, Hudspeth AJ, Seidman CE, Morton CC, Seidman JG: Mutations in a novel cochlear gene cause DFNA9, a human nonsyndromatic deafness with vestibular dysfunction. Nat Genet 1998;20:299–303.
25.
Schuknecht HF, Gacek MR: Cochlear pathology in presbycusis. Ann Otol Rhinol Laryngol 1993;102:1–16.
26.
Shimada A, Ebisu M, Morita T, Takeuchi T, Umemura T: Age-related changes in the cochlea and cochlear nuclei of dogs. J Vet Med Sci 1998;60:41–48.
27.
Shindo S, Ikezono T, Ishizaki M, Sekiguchi S, Mizuta K, Li L, Takumida M, Pawanker R, Yagi T: Spatiotemporal expression of cochlin in the inner ear of rats during postnatal development. Neurosci Lett 2008;444:148–152.
28.
Slepecky NB, Savage JE, Yoo TJ: Localization of type II, IX and V collagen in the inner ear. Acta Otolaryngol 1992;112:611–617.
29.
Usami S, Takahashi K, Yuge I, Ohtsuka A, Namba A, Abe S, Fransen E, Patthy L, Otting G, Van Camp G: Mutations in the COCH gene are a frequent cause of autosomal dominant progressive cochlea-vestibular dysfunction, but not of Ménière’s disease. Eur J Hum Genet 2003;11:744–748.
30.
Usami S, Takumi Y, Suzuki N, Oguchi T, Oshima A, Suzuki H, Kitoh R, Abe S, Sasaki A, Matsubara A: The localization of proteins encoded by CRYM, KIAA1199, UBA52, COL9A3, and COL9A1, genes highly expressed in the cochlea. Neuroscience 2008;154:22–28.
31.
Verhagen WI, Huygen PL, Bles W: A new autosomal dominant syndrome of idiopathic progressive vestibulo-cochlear dysfunction with middle-age onset. Acta Otolaryngol 1992;112:899–906.
32.
Verhagen WI, Huygen PL, Theunissen EJ, Joosten EM: Hereditary vestibulo-cochlear dysfunction and vascular disorder. J Neurol Sci 1989;92:55–63.
33.
Yoo TJ, Tomoda K: Type II collagen distribution in rodents. Laryngoscope 1988;98:1255–1260.
34.
Yoo TJ, Yazawa Y, Floyd R, Tomoda K: Antibody activity in perilymph from rats with type II collagen-induced autoimmune inner ear disease. Ann Otol Rhinol Laryngol Suppl 1984;113:1–2.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.